|
Q4 for RVX and Zenith
|
5
|
Zenith Epigenetics
|
Oct 25, 2016 12:54PM
|
|
Re: Amgen's Acclaimed 20% MACE reduction referred to as "slashing heart attack rates"
|
5
|
Resverlogix Corp.
|
Mar 17, 2017 02:50PM
|
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Oct 24, 2018 01:19PM
|
|
American Diabetes Association Meeting June 22-26, 2018
|
5
|
Resverlogix Corp.
|
Jun 18, 2018 11:02AM
|
|
Re: Thinking back on an older discussion and wishing we had an update - Few items
|
5
|
Resverlogix Corp.
|
Jul 28, 2020 10:40AM
|
|
Selective vs. Non-Selective BET Inhibitors for PAH
|
5
|
Resverlogix Corp.
|
Nov 09, 2019 09:13PM
|
|
Re: AACR 2018
|
5
|
Zenith Epigenetics
|
Feb 22, 2018 10:34AM
|
|
Re: CVOTs on the Horizon
|
5
|
Resverlogix Corp.
|
Oct 04, 2018 11:42AM
|
|
Re: BET inhibitor and BRD4 papers keep piling up
|
5
|
Resverlogix Corp.
|
Sep 26, 2017 05:19AM
|
|
Re: Zenith AGM webcast 9/12/2018
|
5
|
Zenith Epigenetics
|
Sep 10, 2018 06:17PM
|
|
Re: My estimate for Top Line Data Announcement...is a shocker!
|
5
|
Resverlogix Corp.
|
Jun 07, 2019 04:07PM
|
|
Re: An ESC video from youtube that mentions Apabetalone, posted July 10 2019
|
5
|
Resverlogix Corp.
|
Sep 10, 2019 02:21PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 24, 2020 05:56PM
|
|
Re: ...FYI... just saying...
|
5
|
Resverlogix Corp.
|
May 10, 2018 09:47AM
|
|
The good, the bad and the ugly, part 2
|
5
|
Resverlogix Corp.
|
May 24, 2018 08:33PM
|
|
BETonMACE and Aminotransferases
|
5
|
Resverlogix Corp.
|
Aug 14, 2019 07:03AM
|
|
Re: FYI... first quarter RVX events section...
|
5
|
Resverlogix Corp.
|
Jan 21, 2016 01:59PM
|
|
Re: Seeking Alpha post
|
5
|
Resverlogix Corp.
|
Aug 27, 2018 11:03AM
|
|
Zenith ZEN-3694/Enzalutamid... mCRPC Phase 1b/2a Study Published
|
5
|
Zenith Epigenetics
|
Jul 28, 2020 10:52AM
|
|
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
|
5
|
Resverlogix Corp.
|
Jul 06, 2019 12:47PM
|
